NASDAQ
18.81USD
-0.03 (-0.16%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.7B
P/E
—
EPS
—
Beta
1.07
52W range
6.93-20.22
Day range
18.50–19.30
Open
19.19
Prev close
18.84
Volume
2M
Avg volume
2M
Dividend
0.00
IPO
2019-05-07
https://seekingalpha.com/article/4938541-trevi-therapeutics-specialty-beachhead-creates-a-chronic-cough-platform · 8/20/2026+0.80
https://seekingalpha.com/article/4903549-trevi-therapeutics-inc-trvi-presents-at-bank-of-america-global-healthcare-conference-2026 · 5/13/2026+0.00
https://www.marketbeat.com/instant-alerts/trevi-therapeutics-maps-haduvio-chronic-cough-push-sees-cash-runway-into-2030-2026-05-09/ · 5/9/2026+0.80
https://www.globenewswire.com/news-release/2026/04/23/3280367/0/en/Trevi-Therapeutics-to-Participate-in-Upcoming-May-Events.html · 4/23/2026+0.20
https://www.globenewswire.com/news-release/2026/04/17/3275929/0/en/Trevi-Therapeutics-Announces-Pricing-of-150-Million-Underwritten-Offering-of-Common-Stock.html · 4/17/2026
https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-corporate-update-on-november-13-2025-302607029.html · 11/6/2025+0.00
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
